HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks

References

• Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. doi:10.1016/j.ctrv.2011.11.005
   PubMed Web of Science ®Google Scholar
• Hwang KT, Kim J, Jung J, Chang JH, Chai YJ, Oh SW. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res. 2018;17:100.
   Google Scholar
• Gall VA, Philips AV, Qiao N, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells trastuzumab increases HER2 cross-presentation. Cancer Res. 2017;77(19):5374–5383. doi:10.1158/0008-5472.CAN-16-2774
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639. doi:10.1200/JCO.1999.17.9.2639
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–328. doi:10.1016/S1535-6108(04)00083-2
   PubMed Web of Science ®Google Scholar
• Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. Paper presented at: MAbs; 2016.
   Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi:10.1016/S1470-2045(19)30863-0
   PubMed Web of Science ®Google Scholar
• Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):1–14. doi:10.1186/bcr3069
   Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67(18):8882–8890. doi:10.1158/0008-5472.CAN-07-0696
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im S-A, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–584. doi:10.1001/jamaoncol.2020.7932
   PubMed Web of Science ®Google Scholar
• Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):1–12. doi:10.1186/bcr3621
   Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699. doi:10.1016/S1470-2045(14)70178-0
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522. doi:10.1016/S1470-2045(17)30604-6
   PubMed Web of Science ®Google Scholar
• André F, Shahidi J, Lee C, Wang K, Krop I. Phase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer. Ann Oncol. 2019;30:iii63. doi:10.1093/annonc/mdz100.048
   Web of Science ®Google Scholar
• Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154. doi:10.1056/NEJMoa2115022
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803–814. doi:10.1038/onc.2008.432
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. doi:10.1056/NEJMoa064320
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–1130. doi:10.1200/JCO.2008.21.4437
   PubMed Web of Science ®Google Scholar
• Tiwari SR, Mishra P, Abraham J. Neratinib, a novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16(5):344–348. doi:10.1016/j.clbc.2016.05.016
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng Y-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138. doi:10.1200/JCO.20.00147
   PubMed Web of Science ®Google Scholar
• Kulukian A, Lee P, Taylor J, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976–987. doi:10.1158/1535-7163.MCT-19-0873
   PubMed Web of Science ®Google Scholar
• Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–329. doi:10.1016/j.annonc.2021.12.005
   PubMed Web of Science ®Google Scholar
• Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharma Sci. 2017;110:51–61. doi:10.1016/j.ejps.2017.01.021
   PubMed Web of Science ®Google Scholar
• Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245–1255. doi:10.1016/j.annonc.2021.06.024
   PubMed Web of Science ®Google Scholar
• Perez EA, López-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016;18(1):1–13. doi:10.1186/s13058-016-0773-6
   PubMedGoogle Scholar
• Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471. doi:10.1016/S1470-2045(13)70130-X
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Rizwanullah M, Im S-A, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 2017;35(26):3030–3038. doi:10.1200/JCO.2016.70.6267
   PubMed Web of Science ®Google Scholar
• Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–2835. doi:10.1200/JCO.2017.76.7863
   PubMed Web of Science ®Google Scholar
• Butterbaugh S, Patel R, Romond E, Mathew A. Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue. Ann Oncol. 2017;28(12):3098–3099. doi:10.1093/annonc/mdx532
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742. doi:10.1016/S1470-2045(17)30312-1
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Iwata H, Taira N, et al. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). Cancer Sci. 2022;113(9):3169–3179. doi:10.1111/cas.15474
   PubMed Web of Science ®Google Scholar
• Manich CS, O’Shaughnessy J, Aftimos P, et al. LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32:S1288. doi:10.1016/j.annonc.2021.08.2088
   Google Scholar
• Schettini F, Conte B, Buono G, et al. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open. 2021;6(2):100099. doi:10.1016/j.esmoop.2021.100099
   PubMed Web of Science ®Google Scholar
• Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136(1):153–160. doi:10.1007/s10549-012-2243-x
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Zahrieh D, Price K, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935–944. doi:10.1093/annonc/mdl064
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–4843. doi:10.1158/1078-0432.CCR-10-2962
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, O’Shaughnessy J, Mason G, et al. Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERsCNS metastasis and HER2-positive MBC from SystHERs. Clin Cancer Res. 2019;25(8):2433–2441. doi:10.1158/1078-0432.CCR-18-2366
   PubMed Web of Science ®Google Scholar
• Deshpande K, Buchanan I, Martirosian V, Neman J. Clinical perspectives in brain metastasis. Cold Spring Harb Perspect Med. 2020;10(6):a037051. doi:10.1101/cshperspect.a037051
   PubMed Web of Science ®Google Scholar
• Stavrou E, Winer E, Lin N. How we treat HER2-positive brain metastases. ESMO Open. 2021;6(5):100256. doi:10.1016/j.esmoop.2021.100256
   PubMed Web of Science ®Google Scholar
• Percy DB, Ribot EJ, Chen Y, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011;46(11):718. doi:10.1097/RLI.0b013e318226c427
   PubMed Web of Science ®Google Scholar
• Olson E, Abdel-Rasoul M, Maly J, Wu C, Lin N, Shapiro C. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24(6):1526–1533. doi:10.1093/annonc/mdt036
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Esteva F, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242–1248. doi:10.1093/annonc/mdn036
   PubMed Web of Science ®Google Scholar
• Swain S, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–1121. doi:10.1093/annonc/mdu133
   PubMed Web of Science ®Google Scholar
• Lin NU, Kumthekar P, Sahebjam S, et al. Abstract P1-18-03: pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): primary efficacy analysis results from the phase II PATRICIA study. Cancer Res. 2020;80(4_Supplement):P1-18-03-P11-18–03.
   Web of Science ®Google Scholar
• Montemurro F, Ellis P, Anton A, et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92–102. doi:10.1016/j.ejca.2018.12.022
   PubMed Web of Science ®Google Scholar
• Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–1459. doi:10.1158/1078-0432.CCR-08-1080
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-1
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer. 2017;84:141–148. doi:10.1016/j.ejca.2017.07.024
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081. doi:10.1200/JCO.18.01511
   PubMed Web of Science ®Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610. doi:10.1200/JCO.20.00775
   PubMed Web of Science ®Google Scholar
• Metzger Filho O, Leone J, Li T, et al. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020;31(9):1231–1239. doi:10.1016/j.annonc.2020.05.014
   PubMed Web of Science ®Google Scholar
• Borges VF, Ferrario C, Aucoin N, et al. Tucatinib combined with Ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4(9):1214–1220. doi:10.1001/jamaoncol.2018.1812
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/S1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Kim S-B, Chung W-P, et al. Abstract GS3-01: trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Res. 2022;82(4_Supplement):GS3-01-GS03–01. doi:10.1158/1538-7445.SABCS21-GS3-01
   Web of Science ®Google Scholar
• Pérez-García JM, Batista MV, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro-Oncology. 2022;2022:215.
   Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;2022:1–8.
   Google Scholar
• Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Safety. 2008;31(6):459–467. doi:10.2165/00002018-200831060-00002
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Ponde N, Procter M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020;179(1):161–171. doi:10.1007/s10549-019-05453-z
   PubMed Web of Science ®Google Scholar
• Ewer MS, Vooletich MT, Durand J-B, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–7826. doi:10.1200/JCO.2005.13.300
   PubMed Web of Science ®Google Scholar
• Davis CC, Zelnak A, Eley JW, Goldstein DA, Switchenko JM, McKibbin T. Clinical utility of routine cardiac monitoring in breast cancer patients receiving trastuzumab. Ann Pharmacothe. 2016;50(9):712–717. doi:10.1177/1060028016654160
   PubMed Web of Science ®Google Scholar
• Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333–e465. doi:10.1093/ehjci/jeac106
   PubMed Web of Science ®Google Scholar
• Khoury K, Lynce F, Barac A, et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat. 2021;185(3):863–868. doi:10.1007/s10549-020-06053-y
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen JJ, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–5546. doi:10.1200/JCO.2009.23.3734
   PubMed Web of Science ®Google Scholar
• Gradishar W, Moran M, Abraham J. NCCN clinical practice guidelines in oncology: breast cancer, version 2.2022. 2022:1.
   Google Scholar
• Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):347–354. doi:10.1007/s10549-012-2157-7
   PubMed Web of Science ®Google Scholar
• Raedler LA. Kadcyla (Ado-trastuzumab Emtansine): first antibody-drug conjugate approved for the treatment of HER2-positive metastatic breast cancer. 2022.
   Google Scholar
• Powell C, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO open. 2022;7(4):100554. doi:10.1016/j.esmoop.2022.100554
   PubMed Web of Science ®Google Scholar
• Canino F, Omarini C, Cerma K, et al. Ocular toxicity in breast cancer management: manual for the oncologist. Clin Breast Cancer. 2022;22:289–299. doi:10.1016/j.clbc.2022.02.002
   PubMed Web of Science ®Google Scholar
• Banerji U, van Herpen CM, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi:10.1016/S1470-2045(19)30328-6
   PubMed Web of Science ®Google Scholar
• Modi N, Danell N, Perry R, et al. Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer. ESMO Open. 2022;7(3):100475. doi:10.1016/j.esmoop.2022.100475
   PubMed Web of Science ®Google Scholar
• Cortés J, Baselga J, Im Y-H, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013;24(10):2630–2635. doi:10.1093/annonc/mdt274
   PubMed Web of Science ®Google Scholar
• Welslau M, Diéras V, Sohn JH, et al. Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Cancer. 2014;120(5):642–651. doi:10.1002/cncr.28465
   PubMed Web of Science ®Google Scholar
• Curigliano G, Dunton K, Rosenlund M, et al. 163O patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC). Ann Oncol. 2022;33:S196–S197. doi:10.1016/j.annonc.2022.03.182
   Web of Science ®Google Scholar
• Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–1059. doi:10.1001/jamaoncol.2015.2639
   PubMed Web of Science ®Google Scholar
• Federico W, Carlos L, Diego E, et al. Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: a systematic review. Crit Rev Oncol Hematol. 2022;103747. doi:10.1016/j.critrevonc.2022.103747
   PubMed Web of Science ®Google Scholar
• Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA mutations drive therapeutic resistance in human epidermal growth factor receptor 2–positive breast cancer. JCO Precis Oncol. 2022;6:e2100370. doi:10.1200/PO.21.00370
   PubMed Web of Science ®Google Scholar
• Ciruelos E, Villagrasa P, Pascual T, et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA TrialPalbociclib and trastuzumab in HER2-positive breast cancer. Clin Cancer Res. 2020;26(22):5820–5829. doi:10.1158/1078-0432.CCR-20-0844
   PubMed Web of Science ®Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295. doi:10.1016/S1470-2045(20)30465-4
   PubMed Web of Science ®Google Scholar
• Dokter WH, Dijcks FA, Groothuis PG, et al. SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs). Cancer Res. 2020;80(16_Supplement):4043. doi:10.1158/1538-7445.AM2020-4043
   Web of Science ®Google Scholar
• Hurvitz SA, Park H, Frentzas S, et al. Safety and Unique Pharmacokinetic Profile of ARX788, a Site-Specific ADC, in Heavily Pretreated Patients with HER2-Overexpresing Solid Tumors: Results from Two Phase 1 Clinical Trials. Wolters Kluwer Health; 2021.
   Google Scholar
• Yan M, Lv H, Niu L, et al. Anti-HER2 Antibody Inetetamab Plus Camrelizumab and Utidelone for Pretreated HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter, Phase 2 Study. American Society of Clinical Oncology; 2022.
   Google Scholar
• Zhang J, Ji D, Cai L, et al. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of Patients with HER2-positive metastatic breast cancer: results from a phase I StudyHER2-targeted bispecific antibody KN026 in MBC. Clin Cancer Res. 2022;28(4):618–628. doi:10.1158/1078-0432.CCR-21-2827
   PubMed Web of Science ®Google Scholar
• Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335–1344. doi:10.1080/10717544.2022.2069883
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive and HER2-Low Expressing Advanced or Metastatic Breast Cancer: A Pooled Analysis of Two Studies. Wolters Kluwer Health; 2021.
   Google Scholar